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Introduction
Almost 35 years since the ﬁrst published reports of AIDS, the HIV
epidemic continues; globally 2.1 million new infections occurred
in 2013 [1]. The epidemic remains a signiﬁcant challenge and
prevalence amongst men who have sex with men (MSM)
continues to increase in many countries [2,3]. There is an ongoing
need for effective methods of prevention. A wide range of tools
is needed in varying social and economic contexts, and against
different modes of transmission. Recent advances have
concentrated on biomedical approaches to prevention, including
the use of antiretroviral therapy (ART) prior to possible exposure
to HIV: pre-exposure prophylaxis (PrEP).
Drug prophylaxis is already frequently and successfully used in a
variety of other settings, including the prevention of malaria and
the oral contraceptive pill. Both oral and topical (to vagina or
rectum) PrEP have been tested. In studies of oral PrEP, tenofovir
(TDF) and tenofovir–emtricitabine (TDF-FTC) have been
investigated. In this review we  focus only on oral PrEP, for which
more data are available, and for which the drugs that have been
studied are currently available.
Evidence
The results of 10 randomised controlled trials (RCTs) of oral PrEP
are available; they are summarised in Table 1. All studies
investigated daily oral PrEP, with the exception of iPERGAY,
which investigated ‘on demand’ PrEP timed around the period of
exposure [4]. Of note, all studies combined PrEP with safer sex
counselling and STI testing, highlighting the importance of PrEP
within a package of holistic care.
The populations investigated include MSM and transgender
women (TGW) [4—7], heterosexual men and women [8,9],
heterosexual women only [10—12] and people who inject drugs
(PWID) [13].
The overall estimate for the efﬁcacy of oral PrEP in these studies
ranges widely from -49% to 86% [5,12]. The discrepancy in
results is almost certainly explained by adherence. In the two
studies that were stopped early due to futility, drug was detected
in less than 40% of participants [11,12]. However, adherence was
also imperfect in studies that showed high efﬁcacy (PROUD) [5].
PROUD showed an 86% reduction in HIV transmission in the
intervention group, despite the fact that only 56% of intervention
participants had enough drugs prescribed for full adherence [5].
More work is needed to establish the necessary frequency and
dosing in order to gain optimal levels of protection. In addition,
participant gender may contribute to discrepant overall results as
TDF concentrates less well in vaginal tissue compared to rectal
tissue [14]. This may mean that the required level of adherence
to achieve efﬁcacy may be higher for women.
Organisational responses
The US Food and Drug Administration (FDA) became the ﬁrst
national body to approve oral PrEP in 2012, which was
subsequently followed by Centre for Disease Control (CDC)
guidelines in 2014 [15,16]. The guidelines speciﬁed that PrEP
should be twinned with a risk-reduction strategy to encourage
use in combination with safer sex practices [15]. PrEP was
approved for people at ‘substantial risk’ of HIV, including
negative partners of any gender in serodiscordant relationships,
high-risk MSM and PWID [16]. There is a relatively low threshold
for the classiﬁcation of ‘substantial risk’ and reasons include
recent STI, high number of partners and inconsistent
condom use.
Uptake of PrEP in the US has been slower than anticipated,
possibly due to cost barriers and limited awareness amongst
patients [17]. Analysis of pharmacy data indicates that around
3,000 people were prescribed PrEP in the ﬁrst 2 years
post-approval [18]. Initially over 40% of patients receiving PrEP
were women [18], but more recent data indicate the proportion
of men is increasing [19].
In the light of new data, the World Health Organization (WHO)
lifted their initial requirement that PrEP was prescribed within a
demonstration project [20]. In 2014, PrEP was included
alongside other prevention tools such as condoms and
peer-based education programmes in the WHO consolidated
guidelines [21].
Outside the US, prescribing PrEP is more complicated, since no
other countries have licensed the use of ART as PrEP. However,
lack of a licence has not prevented the widespread use of ART as
post-exposure prophylaxis (PEP), for which there is no
randomised controlled trial data or indicated licence in many
countries including the UK.
Despite evidence on the efﬁcacy of PrEP, organisational
responses have been notably cautious. The European Centre for
Disease Control (ECDC), the British HIV Association (BHIVA) and
the British Association of Sexual Health and HIV (BASHH) all
issued public statements between 2012 and 2014 which
acknowledged efﬁcacy, but did not recommend widespread use
at that point [22,23]. This was due to a number of concerns
including adherence, behaviour change and cost. Following
continuing publications showing strong evidence of efﬁcacy, the
potential use of PrEP is currently under review in many countries
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and recommendations may change in the near future.
Issues
STIs/behaviour
Evidence as to whether PrEP will increase risk-taking behaviour
and sexually transmitted infection (STI) incidence is mixed. Some
studies have shown no evidence of increased risk-taking
behaviour, such as a greater number of partners and condomless
sex [6,8,11]. However, these results came from studies where
participants were blinded as to whether they were taking active
drug, and at a time when efﬁcacy of PrEP was unknown.
Conversely, PARTNERS PrEP showed that when participants were
unblinded, there was an increase in the frequency of sex with
non-primary partners, although no increase in the frequency of
condomless sex and no signiﬁcant difference in diagnosis of STIs
was observed [9]. In the open-labelled extension of iPREX,
frequency of condomless sex and number of sexual partners was
the same in groups receiving and not receiving PrEP [24].
PROUD aimed to understand PrEP use in a real-world setting in
which participants knew when they were taking an active drug.
Results showed that there was no signiﬁcant difference between
the immediate and deferred groups in terms of STI diagnoses,
and reported sexual behaviour [5].
It is important to remember that PrEP only protects against HIV.
These results show that although the use of PrEP does not
necessarily lead to an increased risk, the act of seeking PrEP
reﬂects that the patient identiﬁes themselves as at high risk for
HIV infection and, therefore, other STIs. The risk of other STIs
may be less substantial where PrEP is used in the context of a
monogamous relationship by serodiscordant partners. This
highlights the importance of using PrEP in combination with
regular STI screens, in addition to HIV testing and other HIV
prevention strategies. If PrEP were to be rolled out without being
part of a broader HIV prevention package, this could have a
detrimental impact on risk behaviour and STI incidence. Any
services that introduce PrEP will also need to ensure that PrEP
is accessible to groups under-represented in PrEP clinical trials,
in particular black and minority ethnic groups and TGW.
Resistance
Potential resistance has been repeatedly cited as a key concern
around PrEP (Table 1). For participants taking PrEP, we calculate
that resistance occurred in 4% (9/221) of cases where HIV was
transmitted after enrolment. Resistance was observed in 3%
(2/75) of participants in the intervention arm of TDF-only
groups, compared to 5% (7/146) of those in TDF-FTC groups.
Resistance was particularly notable in participants undergoing
seroconversion at the time of enrolment. In the TDF-FTC groups,
20 newly diagnosed cases of HIV were identiﬁed as having
primary HIV at enrolment, among which resistance was observed
in 9 (45%). In the TDF-only groups 20% (2/10) of participants
with primary HIV at enrolment had resistant virus. A logical
response might be to exclude anyone at risk of seroconversion
from taking PrEP; however, since recent condomless sex is a key
indication for PrEP, this approach is not practical and would
exclude those who may beneﬁt the most. An alternative may be
to alert patients of this possibility beforehand and to advise them
to seek medical advice immediately should they feel unwell in the
weeks following PrEP initiation.
The impact of a single genotype resistance in high-income
countries is minimal as there is a wide range of ART available.
However, such resistance could be highly problematic in low- and
middle-income countries where the available drug regimens are
limited. When PrEP is used in a real-world setting, with less
frequent testing and potentially poorer adherence, further
resistance may be seen. It is vital that as countries license PrEP,
they also initiate effective resistance surveillance systems to
monitor resistance trends and inform future practice.
Side effects/toxicity
In both the TDF and TDF-FTC groups, the most commonly
reported adverse events were gastrointestinal symptoms: nausea,
vomiting, diarrhoea and abdominal pain [6,8]. Changes in renal
function were also observed in some studies, but they tended to
be mild and occurred in few cases [12,13]. Signiﬁcant differences
in renal function between intervention and control groups were
only observed in the FEM PrEP and VOICE studies [11,12].
In keeping with their use as HIV treatment, both TDF and
TDF-FTC appear safe for use as PrEP, although long-term data
are lacking. Conversely, the low adherence seen in some studies
may lead to an underestimation of the true prevalence of adverse
effects. Full assessment of side effects and toxicity remains
incomplete and long-term follow-up data are needed.
Cost-effectiveness
In the context of ageing populations and limited resources, health
systems are under signiﬁcant ﬁnancial pressure. As a result, the
potential cost of PrEP as an HIV prevention strategy remains a
controversial issue.
Despite the cost, PrEP has the potential to be a cost-effective
addition to existing HIV prevention strategies when used in the
right setting, and targeted at high-risk populations [25]. It is also
important to note that PrEP is unlikely to be taken life-long;
instead it may be accessed during seasons of risk, including use
of PrEP as a bridge to ART [9].
Adherence is key to achieving efﬁcacy, and therefore also key to
cost-effectiveness. Development of interventions to support
adherence will beneﬁt patients in terms of outcomes, health
services in terms of cost, and public health in terms of onward
transmission of HIV.
In spite of increasing evidence for the effectiveness of PrEP and
models showing cost-effectiveness, this does not always relate to
affordability. The main limiting factor in terms of affordability
remains the price of the drugs [26,27], which will reduce as these
drugs come off patent in the coming years.
Health systems
In the UK, there is a well-established sexual health service, which
is an ideal setting for delivering PrEP. However, this is not
replicated in health systems in other countries. For example,
women in the US may receive sexual health services from
gynaecologists, and infection disease practitioners often treat
people only when they are HIV positive, so HIV-negative MSM
and TGW may fall between services. There is no clear pathway
for PrEP within the US health system which may lead to
fragmented service provision and which can already be observed
in the wide range of specialties that have been prescribing PrEP
in the US since approval [18].
Conclusion
In this new and emerging area of research, long-term data are
lacking. PrEP remains controversial to some and has yet to be
licensed in the UK. There remain some issues that need to be
resolved, including cost-effectiveness, resistance and potential
toxicity. However, evidence on the efﬁcacy of PrEP is compelling.
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The bottom line in HIV prevention is knowing your HIV status;
wide access to testing needs to be available for all. Regular testing
and counselling must be provided alongside PrEP in order to
ensure that it is effective. If this is achieved, and PrEP is delivered
in conjunction with other HIV prevention strategies, then PrEP
has the potential to make a real impact on the HIV epidemic.
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